Transgene is using two companion tests, one being developed by Beckman Coulter and another by Ventana Medical Systems, to pick best responders to its investigational non-small cell lung cancer drug TG4010.

The immunohistochemistry test developed by Ventana will allow Transgene to identify patients expressing mucin 1-positive tumor cells in clinical trials. TG4010 was designed to target MUC1, and the IHC assay will be used to select patients to be enrolled in an upcoming Phase IIb/III trial for the drug.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.